Seroatlas · Human Serome Atlas

FN3K

Fructosamine-3-kinase

Also known as: FN3K_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H479
Gene: FN3K
Ensembl: ENSG00000167363
Chromosome: 17
Canonical length: 309 aa
Protein class: Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
Subcellular location: Mitochondria

OverviewNCBI Gene

A high concentration of glucose can result in non-enzymatic oxidation of proteins by reaction of glucose and lysine residues (glycation). Proteins modified in this way, fructosamines, are less active or functional. This gene encodes an enzyme which catalyzes the phosphorylation of fructosamines which may result in deglycation. [provided by RefSeq, Feb 2012]

Canonical amino-acid sequenceUniProt

309 residues, UniProt reviewed canonical sequence.

>Q9H479|FN3K
     1  MEQLLRAELR TATLRAFGGP GAGCISEGRA YDTDAGPVFV KVNRRTQARQ MFEGEVASLE
    61  ALRSTGLVRV PRPMKVIDLP GGGAAFVMEH LKMKSLSSQA SKLGEQMADL HLYNQKLREK
   121  LKEEENTVGR RGEGAEPQYV DKFGFHTVTC CGFIPQVNEW QDDWPTFFAR HRLQAQLDLI
   181  EKDYADREAR ELWSRLQVKI PDLFCGLEIV PALLHGDLWS GNVAEDDVGP IIYDPASFYG
   241  HSEFELAIAL MFGGFPRSFF TAYHRKIPKA PGFDQRLLLY QLFNYLNHWN HFGREYRSPS
   301  LGTMRRLLK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FN3K can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.26
Highest tissue expression: 66 nTPM

Expression across tissuesHPA

Tissue

spinal cord: 66 nTPM
cerebral cortex: 58 nTPM
midbrain: 57 nTPM
basal ganglia: 55 nTPM
amygdala: 50 nTPM
kidney: 49 nTPM

Single-cell type

somatotrophs: 103 nCPM
retinal ganglion cells: 89 nCPM
proximal tubule cells: 73 nCPM
müller glia: 57 nCPM
adrenal cortex cells: 48 nCPM
lactotrophs: 48 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

white matter: 132 nTPM
cerebellum: 106 nTPM
medulla oblongata: 104 nTPM
basal ganglia: 103 nTPM
pons: 101 nTPM
midbrain: 89 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.36
gnomAD pLI: 0
gnomAD missense Z: 0.05
DepMap mean gene effect: 0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

epithelial cell differentiation
post-translational protein modification
fructosamine metabolic process
fructoselysine metabolic process
protein deglycation

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FN3K as an antibody target. Whether an autoantibody or antibody against FN3K could matter depends on whether native FN3K is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FN3K is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label FN3K as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...